Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors

PLoS One
http://www.plosone.org/
[Accessed 12 Jan 2019]

Research Article
Involving patients and the public in medical and health care research studies: An exploratory survey on participant recruiting and representativeness from the perspective of study authors
Jonas Lander, Holger Langhof, Marie-Luise Dierks
Research Article | published 07 Jan 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0204187
Abstract
Research on patient and public involvement so far concentrates on defining involvement, describing its methods, and analyzing involvement practices in various individual research disciplines. There is little empirical data on the process of and aims for selecting (lay) PPI participants, and to what extend they can and should be representative of the population at large. To explore practices and perceptions on these issues and on future PPI conduct more generally, we sent an electronic survey to authors who published involvement activities as part of their studies in medical and social science journals. We identified such authors with a systematic search of five databases and applied descriptive statistics for analysis. Of those who returned the survey (n = 127 of 315; 40%), most had previously conducted involvement activities (73%). 45% reported more than one type of involvement, e.g. consultation and deliberation and participation (14%) and to have recruited more than one type of participant for their PPI activity (56%), e.g. ‘lay publics’ and ‘expert publics’ (33% of 71). Representativeness was often seen as a crucial objective when selecting PPI participants, while less than half found it very easy (9%) or rather easy (34%) to select participants. Many respondents considered achieving good representativeness difficult (52%) or very difficult (17%). They identified significant respective challenges and desired more guidance on various aspects of planning and conducting PPI (56%). 55% thought that the concept of “involvement” should be changed or improved. We conclude that recruiting lay people for PPI activities and deciding about and handling representativeness are controversial in current PPI practice, given the manifold challenges mentioned by the survey respondents. Our findings may inform further research particularly regarding–the potentially many cases of–unpublished PPI.

 

Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation

PLoS One
http://www.plosone.org/
[Accessed 12 Jan 2019]

Research Article
Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation
Benjamin Speich, Nadine Schur, Dmitry Gryaznov, Belinda von Niederhäusern, Lars G. Hemkens, Stefan Schandelmaier, Alain Amstutz, Benjamin Kasenda, Christiane Pauli-Magnus, Elena Ojeda-Ruiz, Yuki Tomonaga, Kimberly McCord, Alain Nordmann, Erik von Elm, Matthias Briel, Matthias Schwenkglenks, a collaboration of the MARTA (MAking Randomized Trials Affordable) and ASPIRE (Adherence to Standard Protocol Items: REcommendations for interventional trials) Study Groups
Research Article | published 11 Jan 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0210669

Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program

PLoS One
http://www.plosone.org/
[Accessed 12 Jan 2019]

Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
Lukas Richter, Daniela Schmid, Elisabeth Eva Kanitz, Ines Zwazl, Eva Pöllabauer, Joanna Jasinska, Heinz Burgmann, Michael Kundi, Ursula Wiedermann
Research Article | published 10 Jan 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0210081

Facilitators and barriers for healthcare providers to recommend HPV vaccination to attendees of public sexually transmitted diseases clinics in Hong Kong, China

PLoS One
http://www.plosone.org/
[Accessed 12 Jan 2019]

Facilitators and barriers for healthcare providers to recommend HPV vaccination to attendees of public sexually transmitted diseases clinics in Hong Kong, China
Ying Ying Lee, Zixin Wang
Research Article | published 09 Jan 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0209942
 
 

Challenges and strategies for developing efficacious and long-lasting malaria vaccines

Science Translational Medicine
09 January 2019  Vol 11, Issue 474
http://stm.sciencemag.org/

Review
Challenges and strategies for developing efficacious and long-lasting malaria vaccines
By James G. Beeson, Liriye Kurtovic, Carlota Dobaño, D. Herbert Opi, Jo-Anne Chan, Gaoqian Feng, Michael F. Good, Linda Reiling, Michelle J. Boyle
Science Translational Medicine09 Jan 2019 Restricted Access
New knowledge and strategies are emerging to enable the development of an efficacious and long-lasting vaccine against malaria.
Abstract
Although there has been major recent progress in malaria vaccine development, substantial challenges remain for achieving highly efficacious and durable vaccines against Plasmodium falciparum and Plasmodium vivax malaria. Greater knowledge of mechanisms and key targets of immunity are needed to accomplish this goal, together with new strategies for generating potent, long-lasting, functional immunity against multiple antigens. Implementation considerations in endemic areas will ultimately affect vaccine effectiveness, so innovations to simplify and enhance delivery are also needed. Whereas challenges remain, recent exciting progress and emerging knowledge promise hope for the future of malaria vaccines.

 

Protocol for a systematic review of the effects of interventions for vaccine stock management

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 12 Jan 2019]

Protocol
Protocol for a systematic review of the effects of interventions for vaccine stock management
Inadequate vaccine stock management in health facilities leads to vaccine stock-outs. The latter threatens the success of immunisation programmes. Countries have used various approaches to reduce stock-outs an…
Authors: Chinwe Juliana Iwu, Anelisa Jaca, Leila H. Abdullahi, Ntombenhle Judith Ngcobo and Charles Shey Wiysonge
Citation: Systematic Reviews 2019 8:14
Published on: 8 January 2019

Would immunization be the same without cross-reactivity?

Vaccine
Volume 37, Issue 4  Pages 539-676 (21 January 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4

Review article  Open access
Would immunization be the same without cross-reactivity?
Ivo Vojtek, Philippe Buchy, T. Mark Doherty, Bernard Hoet
Pages 539-549
Abstract
“Cross-reactivity” (the observed immune response against pathogen types not specifically targeted by the vaccine antigen composition) and “cross-protection” (clinical protection against related non-vaccine microorganism types) are vaccinology concepts that are attracting renewed interest in the context of disease prevention. National health authorities are collecting mounting evidence of the importance of cross-reactivity. For some vaccines, this has been substantiated by cross-protection data from clinical studies and/or post-licensure data, where their introduction into immunization programmes has shown beneficial impacts on disease caused by related non-vaccine microorganisms. This knowledge has influenced the way new vaccines are designed, developed, and evaluated in real-life settings. Some of the new vaccines are now designed with the specific aim of having a greater breadth of protection. Ideal vaccine antigens therefore include epitopes with conserved homology across related pathogen types, because it is not always possible to include the antigens of all the individual types of a given pathogen species. The use of novel adjuvants with greater immunostimulatory properties can also contribute to improved overall vaccine cross-reactivity, as could the use of antigen delivery platforms. The growing body of evidence allows us to better understand the full impact of vaccines – beyond vaccine-type disease – which should be taken into consideration when assessing the full value of vaccination programmes.

Assessing the timeliness of vaccine administration in children under five years in India, 2013

Vaccine
Volume 37, Issue 4  Pages 539-676 (21 January 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4

Research article  Abstract only
Assessing the timeliness of vaccine administration in children under five years in India, 2013
Abram L. Wagner, Luke M. Shenton, Brenda W. Gillespie, Joseph L. Mathew, Matthew L. Boulton
Pages 558-564

Variations in reason for intention not to vaccinate across time, region, and by race/ethnicity, NIS-Teen (2008–2016)

Vaccine
Volume 37, Issue 4  Pages 539-676 (21 January 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4

Research article  Abstract only
Variations in reason for intention not to vaccinate across time, region, and by race/ethnicity, NIS-Teen (2008–2016)
Jacqueline M. Hirth, Erika L. Fuchs, Mihyun Chang, Maria E. Fernandez, Abbey B. Berenson
Pages 595-601

Variations in reason for intention not to vaccinate across time, region, and by race/ethnicity, NIS-Teen (2008–2016)

Vaccine
Volume 37, Issue 4  Pages 539-676 (21 January 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4

Research article  Abstract only
Variations in reason for intention not to vaccinate across time, region, and by race/ethnicity, NIS-Teen (2008–2016)
Jacqueline M. Hirth, Erika L. Fuchs, Mihyun Chang, Maria E. Fernandez, Abbey B. Berenson
Pages 595-601

The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains

Vaccine
Volume 37, Issue 4  Pages 539-676 (21 January 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/4

Research article  Abstract only
The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains
Patrick T. Wedlock, Elizabeth A. Mitgang, Fayad Elsheikh, Jim Leonard, … Bruce Y. Lee
Pages 645-651

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Frontiers in Immunology
2019   doi: 10.3389/fimmu.2019.00008
Strategies to Improve Cancer Vaccine Efficacy
K Vermaelen –
More than many other fields in medicine, cancer vaccine development has been plagued by a wide gap between the massive amounts of highly encouraging preclinicalencouraging preclinical data on one hand, and the disappointing clinical results on the other. It is clear now that traditional approaches from the infectious diseasesdiseases’ vaccine field cannot be borrowed as such to treat cancer.
In this review we will highlights some of the strategies developed to improve vaccine formulations for oncology, including research into more powerful or “smarter” adjuvants to elicit anti-tumoral cellular immune responses.
As an illustration of the difficulties in translating smart preclinical strategies into real benefit for the cancer patient, we will discuss the difficult road of vaccine development in lung cancer is given as example.
Finally, an outline is provided of we will provide an overview of the combinatorial strategies that leverage the increasing knowledge on tumor-associated immune suppressive networks. Indeed, combining with drugs that target the dominant immunosuppressive pathway in a given tumor promises to will unlock the true power of cancer vaccines and potentially offer long-term protection from disease relapse.
 
 

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
The Economist
http://www.economist.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
New Yorker
http://www.newyorker.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 12 Jan 2019
[No new, unique, relevant content]
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 12 Jan 2019

Opinions
Italy’s right wing is waging a dangerous attack on vaccinations
Michael Gerson · Dec 10, 2018
… Italy’s right-wing coalition government — composed of conservatives and Internet-based populists (including former communists) — has provided a political home for the anti-vaccination movement. The hard core of that movement, according to public-health surveys, is quite small. But its arguments reinforce the questions and fears of a broader 15 to 20 percent of the Italian population who are seriously hesitant about vaccination.

A 2017 Italian law expanding the number of mandatory vaccinations from four to 10 produced significantly greater coverage, as well as a populist backlash. Italy’s new interior minister has said the requirements are “useless and in many cases dangerous.” One senator from the government coalition has compared vaccination scars to “branding for beasts.” The new health minister recently sacked the government’s entire, 30-member science advisory panel, presumably to obtain advice more amenable to populist ideology.

The arguments of the Italian anti-vaccination movement are the same as elsewhere. Its members believe vaccinations are somehow associated with either autism, tumors or allergies. Since there is no reputable science to support this view — none at all — they turn to the language of parental choice and “more freedom” for families in health care. And they often add a conspiratorial element, accusing Big Pharma of making a profit from unnecessary vaccinations…

Vaccines and Global Health: The Week in Review :: 05 January 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: vaccines and global health_the week in review_5 jan 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

144th Session of the WHO Executive Board

Milestones :: Perspectives

 

144th Session of the WHO Executive Board

24 January – 1 February 2019 Coordinated Universal Time
Geneva, Switzerland
Selected Agenda Content
EB144/1 – Provisional agenda
EB144/1 (annotated) – Provisional agenda (annotated)

EB144/8 – Public health preparedness and response
Report of the Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme

EB144/9 – Polio Eradication
EB144/10 – Polio Transition

EB144/11 Rev.1 – Implementation of the 2030 Agenda for Sustainable Development

EB144/12 – Universal health coverage
Primary health care towards universal health coverage
EB144/13 – Universal health coverage
Community health workers delivering primary health care: opportunities and challenges
EB144/14 – Universal health coverage
Preparation for the high-level meeting of the United Nations General Assembly on universal health coverage

EB144/17 – Medicines, vaccines and health products
Access to medicines and vaccines
EB144/18 – Medicines, vaccines and health products
Cancer medicines
EB144/19 – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues
Antimicrobial resistance

EB144/21 – Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues
Ending tuberculosis

EB144/23 – Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits
Implementation of decision WHA71(11) (2018)

EB144/24 – Member State mechanism on substandard and falsified medical products

EB144/27 – Promoting the health of refugees and migrants
Draft global action plan, 2019–2023

Ebola – Democratic Republic of the Congo

Milestones :: Perspectives

Ebola – Democratic Republic of the Congo

 
21: Situation report on the Ebola outbreak in North Kivu 
27 December 2018 [Excerpts]
Situation Update
…As of 25 December 2018, a total of 585 EVD cases, including 537 confirmed and 48 probable cases (Table 1), were reported from 16 health zones in the two neighbouring provinces of North Kivu and Ituri (Figure 1), of which 13 reported at least one confirmed case in the last 21 days (5-25 December 2018). Over this period, 117 confirmed cases were reported from 13 health zones, the majority of which were concentrated in major urban centres and towns in Katwa (30), Komanda (20), Beni (15), Butembo (15), and Mabalako (15), which remain the main hotspots of this outbreak.

Trends in case incidence reflect the continuation of the outbreak across these geographically dispersed areas. The general decrease in the weekly incidence observed in Beni since late October is continuing; however, the outbreak is intensifying in Butembo and Katwa, and new clusters have emerged in other health zones.

Forty-one additional deaths among confirmed and probable cases occurred since our last report on 18 December 2018. Overall, 356 cases have died (case fatality 61%), including 308 among confirmed cases. As of 25 December 2018, 201 patients have recovered and been discharged from ETCs.

A healthcare worker from Mabalako has been reported among the new cases, bringing the number of healthcare workers affected to 54, with 18 deaths…

Case management

On 24 November 2018, MoH announced the launch of a randomized control trial for Ebola therapeutics. This first-ever multi-drug randomized control trial within an outbreak setting, is an important step towards finding an effective evidence-based treatment for Ebola. The trial is coordinated by WHO and led and sponsored by the Democratic Republic of the Congo’s National Institute for Biomedical Research (INRB) which is the principal investigator. The trial has begun in the ALIMA Ebola treatment center (ETC) in Beni, where patients are enrolled in the study after obtaining voluntary informed consent.

Other ETCs continue to provide therapeutics under the MEURI (compassionate use) protocol, in collaboration with the MoH and the INRB, together with supportive care measures. WHO is providing technical clinical expertise on-site and is assisting with the creation of a data safety management board. UNICEF is providing nutritional treatment and psychological support for all hospitalized patients.

As of 25 December 2018, a total of 131 patients were hospitalised in transit centres and ETCs, of whom 29 were laboratory confirmed.

…Implementation of ring vaccination protocol
On 25 December 2018, 138 contacts were vaccinated, along with 201 contacts of contacts and 62 front line workers in 12 vaccination centres.
From 17 to 26 December 2018, 5,491 new people were vaccinated, The cumulative number of people vaccinated as of 26 December 2018 was 53 610.
Vaccination rings were opened around confirmed cases in Vutetse, Kanzulinzuli, Keyshero, Matanda, Muchanga, Vungi, Nyankunde, Wanamahika, and Aloya…

::::::

DONs Ebola virus disease – Democratic Republic of the Congo   
28 December 2018
[Excerpt]
…WHO risk assessment
This outbreak of EVD is affecting north-eastern provinces of the country bordering Uganda, Rwanda and South Sudan. Potential risk factors for transmission of EVD at the national and regional levels include: travel between the affected areas, the rest of the country, and neighbouring countries; the internal displacement of populations. The country is concurrently experiencing other epidemics (e.g. cholera, vaccine-derived poliomyelitis, malaria), and a long-term humanitarian crisis. Additionally, the security situation in North Kivu and Ituri at times limits the implementation of response activities. WHO’s risk assessment for the outbreak is currently very high at the national and regional levels; the global risk level remains low. WHO continues to advice against any restriction of travel to, and trade with, the Democratic Republic of the Congo based on currently available information.

As the risk of national and regional spread is very high, it is important for neighbouring provinces and countries to enhance surveillance and preparedness activities. The International Health Regulations (IHR 2005) Emergency Committee has advised that failing to intensify these preparedness and surveillance activities would lead to worsening conditions and further spread. WHO will continue to work with neighbouring countries and partners to ensure that health authorities are alerted and are operationally prepared to respond.

::::::

WHO Director-General concludes New Year visit to Ebola-affected areas in the Democratic Republic of the Congo
3 January 2019, News Release, Geneva
WHO Director-General Dr Tedros Adhanom Ghebreyesus traveled over the New Year to Ebola-affected areas in the Democratic Republic of the Congo (DRC) to review the response at this critical phase. Efforts to end the outbreak are continuing after recent disruptions, but further interruptions could have serious consequences, he warned.

Civil unrest resulted in vandalism to an Ebola transit centre in Beni and several other health facilities last week. The insecurity slowed down vaccinations and epidemiological surveillance and follow-up for several days.

“I’m concerned about the impact of the recent disruptions at this critical moment. This outbreak is occurring in the most difficult context imaginable. To end it the response needs to be supported and expanded, not further complicated. Ebola is unforgiving, and disruptions give the virus the advantage,” said Dr Tedros….

Director of the Wellcome Trust and Chair of WHO’s Research and Development Blueprint Dr Jeremy Farrar joined the mission to see the outbreak first-hand.

“I came away humbled by the dedication of the Ebola responders, but worried by the immense challenges they face in such a complex environment. This outbreak is in a critical phase. It is vital the international community recognizes this and ensures the DRC and WHO have the support needed to ensure this outbreak does not spiral out of control,” Dr Farrar said…

::::::

Statement on disruptions to the Ebola response in the Democratic Republic of the Congo
by Dr Tedros Adhanom Ghebreyesus, WHO Director-General
28 December 2018   Statement  Geneva
WHO and partners are continuing to respond to the Ebola outbreak in North Kivu and Ituri provinces in the Democratic Republic of the Congo, despite a deterioration of the security situation since yesterday morning.

Yesterday our teams in Beni were unable to carry out critical field work, including vaccinations, contact tracing, and following up on alerts of potential new cases. Protests at government buildings in Beni spilled over to an Ebola transit centre, frightening people waiting for Ebola test results and the staff who were caring for them. Staff at the centre temporarily withdrew and most suspected cases were transferred to a nearby treatment centre.

In Butembo, some alerts of potential cases were investigated and confirmed cases were referred to treatment centres but teams were unable to trace contacts or to conduct vaccinations.

Response activities have not been interrupted in other affected areas.

We have reached a critical point in the Ebola response. After an intensification of field activities, we were seeing hopeful signs in many areas, including a recent decrease in cases in Beni.

These gains could be lost if we suffer a period of prolonged insecurity, resulting in increased transmission. That would be a tragedy for the local population, who have already suffered too much.

Our teams in Beni and Butembo are doing everything possible to continue responding, despite the challenging security environment. For example, in Beni, contact tracing is being resumed with the support of local community relays, and WHO is supporting local health authorities to undertake other critical surveillance functions where possible.

In general, the communities in affected areas have been supportive of the response. We ask for everyone to protect health facilities and provide access for responders to the affected populations so that we can stop this outbreak. The population must also have safe access to transit and treatment centres that save lives and stop the spread of Ebola.

Working side by side with the Ministry of Health and our partners, our priority is to end the outbreak. We hope to return to full operations as soon as possible while remaining committed to ensuring the safety of all staff deployed. We cannot afford to take a step back at this critical point in the response

 

Emergencies

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
– No new announcements identified

::::::
::::::

Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies  [to 5 Jan 2019]
Democratic Republic of the Congo
:: 21: Situation report on the Ebola outbreak in North Kivu  27 December 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo   28 December 2018
[See Milestones above for more detail]

Bangladesh – Rohingya crisis
:: Weekly Situation Report 57 – 27 December 2018
[Excerpt]

KEY HIGHLIGHTS
:: About 30 health facilities have received exemption from restricted movement during the election period and will remain open to provide essential health services.
:: About 363 411 people (110.6%) benefited from the OCV campaign including 264,280 people (117.5%) from Rohingya population.
:: Since February 2018 to date, a total of 35,148 BCG doses have been given children and 19 906 Td doses to pregnant women.

SITUATION OVERVIEW
:: There are an estimated 908,000 Rohingya refugees (215,796 families) in Cox’s Bazar, according to the latest Needs and Population Monitoring (NPM) round 12 exercise. The Rohingya refugees continue to arrive in Bangladesh, though the overall influx has slowed since the onset of the crisis in late August 2017. Rohingya refugees have continued to arrive in Bangladesh, though in much fewer numbers than the initial influx in late 2017. More than 15,247 new arrivals were reported from 1 January to 30 November 2018 (source: UNHCR). The refugees continue to face compounding vulnerabilities including health.
:: Over the past one year, WHO and the health sector partners responded to the health needs of the affected populations by supporting government health facilities with human resources, renovations and medical supplies; ensuring availability of essential medicines and other supplies through logistics support; maintaining a strong disease surveillance system; delivering vaccination campaigns and strengthening

 

Syrian Arab Republic
:: SIDA donation helps WHO support health care services in southern Syria [Swedish International Development Cooperation Agency]  27 December 2018

Yemen
:: Cholera and malnutrition in Yemen threatens millions

27 December 2018
…WHO works closely with the Ministry of Health and WASH cluster partners to contain cholera outbreaks, offering technical and logistical support to strengthen disease surveillance, assist diarrhoeal treatment and oral rehydration centres, train health workers on case management, deploy rapid response teams and improve sanitation and access to safe water.
There have been 280,198 suspected cases of cholera since the beginning of 2018, and 372 associated deaths. Children under 5 account fort 32% of the total suspected cases. Cholera has been reported in 22 out of Yemen’s 23 governorates, and 306 out of the country’s 333 districts.

Myanmar – No new announcements identified
Nigeria – No new announcements identified
Somalia – No new announcements identified
South Sudan – No new announcements identified

::::::

WHO Grade 2 Emergencies  [to 5 Jan 2019]
occupied Palestinian territory
:: 1.2 million people in the occupied Palestinian territory are in need of humanitarian health assistance – December 2018

Libya
:: WHO condemns attack on Al Jala Hospital in Benghazi
27 December 2018 – The World Health Organization (WHO) strongly condemns the armed attack on Al Jala Hospital in Benghazi, Libya, on 25 December. The attack resulted in damage to the hospital infrastructure.

Brazil (in Portugese) – No new announcements identified
Cameroon  – No new announcements identified
Central African Republic  – No new announcements identified
Ethiopia – No new announcements identified
Hurricane Irma and Maria in the Caribbean – No new announcements identified
– No new announcements identified
Iraq – No new announcements identified
MERS-CoV – No new announcements identified
Niger – No new announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new announcements identified
Sudan – No new announcements identified
Ukraine – No new announcements identified
Zimbabwe – No new announcements identified

WHO-AFRO: Outbreaks and Emergencies Bulletin, Week 52: 22 – 28 December 2018
The WHO Health Emergencies Programme is currently monitoring 59 events in the region. This week’s edition covers key ongoing events, including:
:: Ebola virus disease outbreak in the Democratic Republic of the Congo
:: Measles in Madagascar
:: Humanitarian crisis in Nigeria.

 
::::::
 

WHO Grade 1 Emergencies  [to 5 Jan 2019]
Afghanistan
Chad
Indonesia – Sulawesi earthquake 2018
Kenya
Lao People’s Democratic Republic
Mali
Namibia – viral hepatitis
Peru
Philippines – Tyhpoon Mangkhut
Tanzania

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic   – No new announcements identified
Yemen – No new announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia 
:: Operational Plan for Rapid Response: Internal Displacement around Kamashi and Assosa (Benishangul Gumuz) and East and West Wollega (Oromia), 26 December 2018

Somalia 
:: Humanitarian Bulletin Somalia, 1 – 31 December 2018

::::::

“Other Emergencies”
Indonesia: Central Sulawesi Earthquake
:: 24 December 2018  –  Central Sulawesi Earthquake & Tsunami – Humanitarian Country Team Situation Report #10 (as of 10 December 2018)

::::::
::::::

Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.

EBOLA/EVD  [to 5 Jan 2019]
http://www.who.int/ebola/en/
:: 19: Situation report on the Ebola outbreak in North Kivu  12 December 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo   13 December 2018
[See Milestones above for more detail]

MERS-CoV [to 5 Jan 2019]
http://who.int/emergencies/mers-cov/en/
No new announcements identified.

Yellow Fever  [to 5 Jan 2019]
http://www.who.int/csr/disease/yellowfev/en/
No new announcements identified.

Zika virus  [to 5 Jan 2019]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.

 

 

WHO & Regional Offices [to 5 Jan 2019]

WHO & Regional Offices [to 5 Jan 2019]

144th Session of the WHO Executive Board
24 January – 1 February 2019 Coordinated Universal Time
Geneva, Switzerland
[See selected agenda content in Milestones above]

 ::::::

 
WHO Director-General concludes New Year visit to Ebola-affected areas in the Democratic Republic of the Congo
3 January 2019, News Release, Geneva
[See Ebola above for detail]

 
Statement on disruptions to the Ebola response in the Democratic Republic of the Congo
by Dr Tedros Adhanom Ghebreyesus, WHO Director-General
28 December 2018   Statement  Geneva
[See Ebola above for detail]

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
Selected Featured News
:: WHO Director-General applauds Uganda’s Ebola preparedness response  03 January 2019
:: Ethiopia launched new guideline for reaching missed tuberculosis cases  27 December 2018

WHO Region of the Americas PAHO
– No new announcement identified

WHO South-East Asia Region SEARO
– No new announcement identified

WHO European Region EURO
– No new announcement identified

WHO Eastern Mediterranean Region EMRO
:: WHO condemns attack on Al Jala Hospital in Benghazi  27 December 2018
:: SIDA donation helps WHO support health care services in southern Syria  27 December 2018

WHO Western Pacific Region
– No new announcement identified

 

CDC [U.S.] – MMWR News Synopsis for Friday, January 4, 2019

CDC/ACIP [to 5 Jan 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
 
MMWR News Synopsis for Friday, January 4, 2019
Human Rabies — Virginia, 2017
While human rabies deaths are rare in the United States, they are still highly prevalent in many other countries. Travelers to other countries should consult the CDC Yellow Book and their medical provider prior to travels to countries where rabies is present, particularly if they are engaging in activities that will put them in close proximity to animals such as dogs, cats, and wildlife. A 65-year-old Virginia resident died from rabies after being bitten by a puppy while vacationing in India. Rabies is a highly lethal virus, but is preventable when medical care and vaccination are sought shortly after an exposure. Unfortunately, the victim did not seek medical care after the bite, and six weeks later developed the first signs of rabies after returning to her home in Virginia. Despite intensive medical care, the victim passed away. Rabies is primarily transmitted by bites from animals when virus in the saliva is introduced into a victim’s body. In very rare occasions, non-bite transmission may occur when saliva infects fresh open wounds or mucous membranes (such as the eyes or mouth). A public health investigation identified 72 hospital staff with suspected exposures to infectious materials; all were advised to receive vaccination.

China CDC :: National Health Commission of the People’s Republic of China

China CDC 
http://www.chinacdc.cn/en/
New website launched…no “news” or “announcements” page identified.

 

National Health Commission of the People’s Republic of China
http://en.nhfpc.gov.cn/
Selected Updates/ Press Releases/ Notices
2019-01-02
Chinese lawmakers suggest publicizing vaccine examination reports
BEIJING — Chinese lawmakers have called for the publication of examination reports on vaccines after they are approved by authorities.
The suggestion was raised on Dec 28 at a penal deliberation on a draft law on vaccine management, which was submitted to the ongoing session of the National People’s Congress Standing Committee for its first reading.
Li Yuefeng, a member of the committee, said it should be stipulated in the draft that a report detailing examination results of a vaccine should be made public to ensure the people’s right to transparency.
Wu Weihua, a committee vice chairperson, advised that the research and development (R&D) of a vaccine should be filed with relevant administrative departments since vaccine R&D may involve virulent or contagious pathogens.
Committee member Wu Heng called for revisions of the draft on tightening supervision and management of logistics, especially on temperature control.
Li Kang, another committee member, said the vaccination centers that offer voluntary vaccinations outside the national vaccination plan should be required by the draft to participate in medical liability insurance.
Other suggestions at the deliberation included toughening the examination and inspection of imported vaccines and making a more specific guideline for vaccine pricing.

Updated: 2018-12-15
China reports 2,826 deaths from infectious diseases in November
(Xinhua)
BEIJING — A total of 2,826 people died as a result of infectious diseases in China in November, according to statistics released by the National Health Commission.
There were 636,722 cases of infectious diseases reported last month.
One case of cholera was reported in November and no cases of plague were reported. No fatalities caused by these diseases have been reported, the commission said.
Cholera and plague are classified as Class A infectious diseases, the most serious classification in China’s Law on the Prevention and Treatment of Infectious Diseases.
A total of 303,714 infections of diseases classified as Class B infectious diseases were reported, resulting in 2,819 deaths in November. Viral hepatitis, tuberculosis, syphilis, gonorrhea and scarlet fever accounted for 93 percent of these cases.
Class C diseases caused seven deaths in November. Foot and mouth disease, infectious diarrhea and influenza were the most prevalent in this category, accounting for 92 percent of cases.

Announcements

Announcements
 
 
BMGF – Gates Foundation  [to 5 Jan 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 5 Jan 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 5 Jan 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
01.03.2019  |
CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa
CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support..
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 5 Jan 2019]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 5 Jan 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 5 Jan 2019]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 5 Jan 2019]
http://www.ema.europa.eu/ema/
News and press releases
04/01/2019
News: Human medicines: highlights of 2018
 
 
European Vaccine Initiative  [to 5 Jan 2019]
http://www.euvaccine.eu/news-events
27 December 2018
TRANSVAC2 success story published by EC
European Commission highlights that EU-funded TRANSVAC2 project is developing infrastructure to support innovation and…
 
 
FDA [to 5 Jan 2019]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
 
 
Fondation Merieux  [to 5 Jan 2019]
http://www.fondation-merieux.org/
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
 
 
Gavi [to 5 Jan 2019]
https://www.gavi.org/
No new digest content identified.
 
 
GHIT Fund   [to 5 Jan 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 5 Jan 2019]
https://www.theglobalfund.org/en/news/
No new digest content identified.
 
 
Hilleman Laboratories   [to 5 Jan 2019]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 5 Jan 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.
 
 
IAVI  [to 5 Jan 2019]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 5 Jan 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 5 Jan 2019]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.
 
 
JEE Alliance  [to 5 Jan 2019]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 5 Jan 2019]
http://www.msf.org/
Selected News; Project Updates, Reports
Access to medicines
Calling on governments to scale up oral TB treatment
Press Release 22 Dec 2018
Geneva — Médecins Sans Frontières (MSF) today welcomed new World Health Organization (WHO) treatment guidelines that recommend drug-resistant tuberculosis (DR-TB) be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.
Two injectable drugs known to cause deafness and other severe side effects are no longer recommended in the new guideline – an important step towards more tolerable treatment for all patients.
The recommended 18 to 20-month treatment regimen includes more potent drugs – bedaquiline, linezolid, levofloxacin and moxifloxacin – that can help improve cure rates, reduce deaths and cause people far fewer side effects.
MSF called on countries with large numbers of people with DR-TB to urgently start implementing these new treatment guidelines for at least half of new DR-TB cases by September 2019, and to make efforts to reach all people in need by March 2020…
 
 
NIH  [to 5 Jan 2019]
http://www.nih.gov/news-events/news-releases
January 2, 2019
NIH study implicates hyperactive immune system in aging brain disorders
— Results suggest a breakdown in brain cell waste system triggers a destructive immune reaction.
 
 
PATH  [to 5 Jan 2019]
https://www.path.org/media-center/
January 1, 2019 by PATH
Community-based HIV testing effective in reaching undiagnosed populations, PATH-led study finds
Lay provider HIV testing in Vietnam offers new model to connect at-risk populations with antiretroviral therapy
Hanoi, Vietnam, January 1, 2019—One in three people living with HIV in Vietnam remain undiagnosed, according to recent estimates. New strategies and models of HIV testing are urgently needed to reach undiagnosed populations and help them enroll in antiretroviral therapy (ART), in Vietnam and throughout the world.
Results from an evaluation study now published in PLOS ONE demonstrate that HIV testing by lay providers can serve as a critical addition to efforts to achieve the United Nations’ 90-90-90 global HIV targets by 2020 and help to cover the “last mile” of HIV services to at-risk populations in Vietnam…
 
 
Sabin Vaccine Institute  [to 5 Jan 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 5 Jan 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
27 December 2018
First Lady of Botswana champions revitalization of HIV prevention among adolescent girls and young women
 
 
UNICEF  [to 5 Jan 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
Lives of children at risk amid heavy fighting and floods in north-west Syria
Nearly 10,000 children fleeing floods in the area
03/01/2019
 
 
Press release
New Year’s Babies: Over 395,000 children will be born worldwide on New Year’s Day – UNICEF
As the calendar turns to 2019, UNICEF calls on nations to meet every newborn’s right to health and survival
31/12/2018
 
 
Press release
World has failed to protect children in conflict in 2018: UNICEF
Widespread violations against children in conflict continue in shocking year-on-year trend
[See Milestones above for detail]
 
 
Vaccine Confidence Project  [to 5 Jan 2019]
http://www.vaccineconfidence.org/
Confidence Commentary:
Reflections for the New Year: Thank you Dr. Frankenstein
Heidi Larson | 28 Dec, 2018
[Excerpt]
2018 has been a year of anniversaries – particularly the devastating “Spanish” influenza pandemic, which peaked in 1918, and the armistice ending the First World War. But it also marked 200 years since the 1818 publication of Mary Shelley’s “Frankenstein; or, The Modern Prometheus”. This is a riveting tale of hubris, of fascination to know more and more, and of man playing God, creating a monster and then abandoning him, leaving to find his own way.

Having neglected his creation, and faced with unanticipated revenge by his own invention, Frankenstein bemoans his regret at ignoring “the duties of a creator towards his creature”.

Shelley’s novel was one of the earliest, if not the first, science fiction novel, with insights into the human condition, and man’s struggle with desire to know more and more, yet unprepared to deal with the consequence. She was writing at the dawn of a new era of electricity, of power, of science and possibility – an era not unlike our own.

Frankenstein offers us a lesson in anticipating the implications of our scientific discovery and innovation, of being too focused on technology and its inherent power, of being perhaps obsessed with the notion of “disruption” as progress, while giving little consideration to its accidentally negative, or even malevolent, consequences.

The bicentenary of Frankenstein struck me as an apt anniversary to reflect and conclude the year on, as we are increasingly confronted with the risks and consequences of social media and global connectivity. The algorithms that live behind the screen, as well as human intentions behind them, are manipulating and polarizing public emotions, fears and perceived truths.

Anonymous or constructed identities are misleading individuals, with bots and trolls embedding the vaccine debates, not just to undermine vaccines, but as a platform – a Trojan Horse – to further destabilize democracy and foster discontent.  In other instances, the spotlight has been on companies – driven by growth – using and abusing personal data generated through social media, for furthering their own profits.

It is no wonder public trust is waning…
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 5 Jan 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 5 Jan 2019]
https://wellcome.ac.uk/news
News | 29 December 2018
Wellcome leaders awarded New Year Honours
Jeremy Farrar, Wellcome’s Director, and Mike Ferguson, Deputy Chair of our Board of Governors, have both been knighted in the New Year’s Honours 2019.
 
 
The Wistar Institute   [to 5 Jan 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 5 Jan 2019]
http://www.oie.int/en/for-the-media/press-releases/2018/
No new digest content identified.
 
 
::::::
 
 
BIO    [to 5 Jan 2019]
https://www.bio.org/insights/press-release
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 5 Jan 2019]
http://www.dcvmn.org/
20 December 2018
Bill Gates: “looking forward to the partnerships we can have over the next decade”
Kunming, 30th October 2018 – Vaccine manufacturers from emerging countries convened in Kunming, China, to consider vaccine industry partnerships to help advance global health initiative. A.Oswald interviewed Bill Gates (by recorded video), reflecting on achievements of the first decade of vaccines…
bill_gates_kunming_video_news.pdf (PDF – 203.3 kb)
 
 
IFPMA   [to 5 Jan 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.
 
 
PhRMA    [to 5 Jan 2019]
http://www.phrma.org/press-room
No new digest content identified.
 
 
Industry Watch    [to 5 Jan 2019]
:: FDA Approves VAXELIS, Sanofi and MSD’s Pediatric Hexavalent Combination Vaccine
PARIS and KENILWORTH, N.J. – December 26, 2018 – The U.S. Food and Drug Administration has approved VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age (prior to the 5th birthday). VAXELIS was developed as part of a joint-partnership between Sanofi and MSD (NYSE: MRK), known as Merck inside the United States and Canada.
Sanofi and MSD are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020…

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

 

 

 

Implementation of Strategies to Improve Human Papillomavirus Vaccine Coverage: A Provider Survey

American Journal of Preventive Medicine
January 2019 Volume 56, Issue 1, p1-178
http://www.ajpmonline.org/current

Research Articles
Implementation of Strategies to Improve Human Papillomavirus Vaccine Coverage: A Provider Survey
Emily B. Walling, Sherry Dodd, Neil Bobenhouse, Evelyn Cohen Reis, Randy Sterkel, Jane Garbutt
p74–83 Published in issue: January 2019

California’s Senate Bill 277: Local Health Jurisdictions’ Experiences With the Elimination of Nonmedical Vaccine Exemptions

American Journal of Preventive Medicine
January 2019 Volume 56, Issue 1, p1-178
http://www.ajpmonline.org/current

California’s Senate Bill 277: Local Health Jurisdictions’ Experiences With the Elimination of Nonmedical Vaccine Exemptions
Health Policy
Salini Mohanty, Alison M. Buttenheim, Caroline M. Joyce, Amanda C. Howa, Daniel Salmon and Saad B. Omer
109(1), pp. 96–101

Trends and Characteristics of Proposed and Enacted State Legislation on Childhood Vaccination Exemption, 2011–2017

American Journal of Preventive Medicine
January 2019 Volume 56, Issue 1, p1-178
http://www.ajpmonline.org/current

Trends and Characteristics of Proposed and Enacted State Legislation on Childhood Vaccination Exemption, 2011–2017
Immunization/Vaccines, Child and Adolescent Health, Health Law, Health Policy, Other Child and Adolescent Health
Neal D. Goldstein, Joanna S. Suder and Jonathan Purtle
109(1), pp. 102–107

 

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 5 Jan 2019)

Research article
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences in their equivalence, manufacturing quality standards and reliability of supply. This necessitates reconsideration of the lowest price policy objective in pharmaceutical decision making. The aim of this study was to develop a Multi-Criteria Decision Analysis (MCDA) framework through a pilot workshop to inform the national procurement of OPPs in Indonesia.
Authors: Andras Inotai, Diana Brixner, Nikos Maniadakis, Iwan Dwiprahasto, Erna Kristin, Agus Prabowo, Alfi Yasmina, Sigit Priohutomo, Bertalan Németh, Kalman Wijaya and Zoltan Kalo
Citation: BMC Health Services Research 2018 18:1003
Published on: 29 December 2018

Epidemiology survey of infectious diseases in North Korean travelers, 2015–2017

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 5 Jan 2019)

Research article
Epidemiology survey of infectious diseases in North Korean travelers, 2015–2017
Up until now, there are limited studies available on the epidemiology of infectious diseases in Democratic People’s Republic of Korea (DPRK, North Korea). However, different types of infectious diseases have been found in North Korean travelers at Dandong port. Entry surveillance data of those North Korean travelers may provide some insight into the probable epidemiology of some infectious diseases in DPRK.
Authors: Pengyu Han, Yanxia Teng, Xiuxin Bi, Jinge Li and Dianxing Sun
Citation: BMC Infectious Diseases 2019 19:13
Published on: 5 January 2019

 

Epidemiology survey of infectious diseases in North Korean travelers, 2015–2017

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 5 Jan 2019)

Research article
Epidemiology survey of infectious diseases in North Korean travelers, 2015–2017
Up until now, there are limited studies available on the epidemiology of infectious diseases in Democratic People’s Republic of Korea (DPRK, North Korea). However, different types of infectious diseases have been found in North Korean travelers at Dandong port. Entry surveillance data of those North Korean travelers may provide some insight into the probable epidemiology of some infectious diseases in DPRK.
Authors: Pengyu Han, Yanxia Teng, Xiuxin Bi, Jinge Li and Dianxing Sun
Citation: BMC Infectious Diseases 2019 19:13
Published on: 5 January 2019

 

African bioethics: methodological doubts and insights

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 5 Jan 2019)

Debate
|   27 December 2018
African bioethics: methodological doubts and insights
A trend called ‘African bioethics’ is growing on the continent due to perceptions of existing bioethics, especially guidelines for international collaborative research, as ‘ethical imperialism’. As a potential alternative to ‘Western Principlism,’ ‘African bioethics’ is supposed to be indigenous to Africa and reflective of African identity. However, despite many positive insights in the on-going discussions, it is feared that the growth of bioethics in Africa lacks a clear direction. Some of the views threaten to distort the essence of bioethics and its development on the continent.
Authors: John Barugahare

Impact of an organization-wide knowledge translation strategy to support evidence-informed public health decision making

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 5 Jan 2019)

Research article
Impact of an organization-wide knowledge translation strategy to support evidence-informed public health decision making
The public health sector is moving toward adopting evidence-informed decision making into practice, but effort is still required to effectively develop capacity and promote contextual factors that advance and …
Authors: Maureen Dobbins, Robyn L. Traynor, Stephanie Workentine, Reza Yousefi-Nooraie and Jennifer Yost
Citation: BMC Public Health 2018 18:1412
Published on: 29 December 2018

New ethical challenges of digital technologies, machine learning and artificial intelligence in public health: a call for papers

Bulletin of the World Health Organization
Volume 97, Number 1, January 2019, 1-72
https://www.who.int/bulletin/volumes/97/1/en/

EDITORIALS
New ethical challenges of digital technologies, machine learning and artificial intelligence in public health: a call for papers
– Diana Zandi, Andreas Reis, Effy Vayena & Kenneth Goodman
http://dx.doi.org/10.2471/BLT.18.227686

Using the polio programme to deliver primary health care in Nigeria: implementation research

Bulletin of the World Health Organization
Volume 97, Number 1, January 2019, 1-72
https://www.who.int/bulletin/volumes/97/1/en/

RESEARCH
Using the polio programme to deliver primary health care in Nigeria: implementation research
– Samuel Bawa, Christine McNab, Loveday Nkwogu, Fiona Braka, Esther Obinya, Michael Galway, Andrew J Mirelman, Kulchumi Isa Hammanyero, Garba Safiyanu, Martin Chukwuji, Kennedy Ongwae, Pascal Mkanda, Melissa Corkum, Lea Hegg, Deanna Tollefson, Sani Umar, Sunday Audu, Hassan Gunda, Modu Chinta, Anne Eudes Jean Baptiste, Murtala Bagana & Faisal Shuaib
http://dx.doi.org/10.2471/BLT.18.211565

National age-of-consent laws and adolescent HIV testing in sub-Saharan Africa: a propensity-score matched study

Bulletin of the World Health Organization
Volume 97, Number 1, January 2019, 1-72
https://www.who.int/bulletin/volumes/97/1/en/

RESEARCH
National age-of-consent laws and adolescent HIV testing in sub-Saharan Africa: a propensity-score matched study
– Britt McKinnon & Ashley Vandermorris
http://dx.doi.org/10.2471/BLT.18.212993

A Vaccine Against Cervical Cancer: Context for the Global Public Health Practitioner

Global Health: Science and Practice (GHSP)
Vol. 6, No. 4   December 27, 2018
http://www.ghspjournal.org/content/current

COMMENTARIES
Open Access
A Vaccine Against Cervical Cancer: Context for the Global Public Health Practitioner
Mary Carol Jennings and Anagha Loharikar
Global Health: Science and Practice December 2018, 6(4):629-634; https://doi.org/10.9745/GHSP-D-18-00222
Many low- and middle-income countries are moving to introduce HPV vaccine into their national immunization programs. To improve coverage, equity, and sustainability, public health officials and practitioners can use planning and implementation lessons learned, including successful school-based delivery strategies, innovative approaches to reach out-of-school girls, best practices for communication and social mobilization, and integration of services to reduce delivery cost. Policy makers, donors, and global partners should continue to consider ways to drive down costs of vaccine procurement.

Factors Associated with Human Papillomavirus Vaccination Among Diverse Adolescents in a Region with Low Human Papillomavirus Vaccination Rates

Health Equity
Volume 2, Issue 1 / December 2018
https://www.liebertpub.com/toc/heq/2/1

Factors Associated with Human Papillomavirus Vaccination Among Diverse Adolescents in a Region with Low Human Papillomavirus Vaccination Rates
Deanna Kepka, Julia Bodson, Djin Lai, Ana Sanchez-Birkhead, Jeannette Villalta, Valentine Mukundente, Fahina Tavake-Pasi, France A. Davis, Doriena Lee, Edwin Napia, Ryan Mooney,
Heather Coulter, and Louisa A. Stark
Pages:223–232
Published Online:1 September 2018
https://doi.org/10.1089/heq.2018.0028

Barriers to HPV Vaccination Among Unvaccinated, Haitian American College Women

Health Equity
Volume 2, Issue 1 / December 2018
https://www.liebertpub.com/toc/heq/2/1

Original Article  Open Access
Barriers to HPV Vaccination Among Unvaccinated, Haitian American College Women
Dudith Pierre-VictorDionne P. StephensAngela OmondiRachel Clarke, Naomie Jean-Baptiste, and  Purnima Madhivanan
Pages:90–97
Published Online:1 June 2018
https://doi.org/10.1089/heq.2017.0028

Rohingya refugees in Bangladesh: the humanitarian response

Humanitarian Exchange Magazine
Number 73,  October 2018
https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/

Rohingya refugees in Bangladesh: the humanitarian response
More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, Mark Bowden outlines the historical, local and national political context in Bangladesh, and its operational implications. Amal de Chickera highlights the links between statelessness and displacement, and the international community’s failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. Puttanee Kangkun and John Quinley document the persistent persecution and denial of rights the Rohingya have faced for decades. Jeff Crisp reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the ‘localisation’ agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people’s needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees’ perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

Mandatory and recommended vaccinations in Poland in the views of parents

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 14, Issue 12, 2018
http://www.tandfonline.com/toc/khvi20/current

Article
Mandatory and recommended vaccinations in Poland in the views of parents
Jolanta Kraśnicka, Elżbieta Krajewska-Kułak, Krystyna Klimaszewska, Mateusz Cybulski, Andrzej Guzowski, Beata Kowalewska, Barbara Jankowiak, Hanna Rolka, Halina Doroszkiewicz & Wojciech Kułak
Pages: 2884-2893
Published online: 12 Oct 2018

Implementation and assessment of vaccination programmes: the importance of vaccination sequence for overall health outcomes

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 14, Issue 12, 2018
http://www.tandfonline.com/toc/khvi20/current

article commentary
Implementation and assessment of vaccination programmes: the importance of vaccination sequence for overall health outcomes
Ane Bærent Fisker & Sanne Marie Thysen
Pages: 2900-2903
Published online: 28 Aug 2018

Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 14, Issue 12, 2018
http://www.tandfonline.com/toc/khvi20/current

review
Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness
Nyi Nyi Soe, Jason J. Ong, Xiaomeng Ma, Christopher K Fairley, Phyu Mon Latt, Jun Jing, Feng Cheng & Lei Zhang
Pages: 3010-3018
Published online: 11 Sep 2018

Exploring immunisation inequities among migrant and refugee children in New Zealand

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 14, Issue 12, 2018
http://www.tandfonline.com/toc/khvi20/current

Article
Exploring immunisation inequities among migrant and refugee children in New Zealand
Nadia A. Charania, Janine Paynter, Arier C. Lee, Donna G. Watson & Nikki M. Turner
Pages: 3026-3033
Published online: 17 Aug 2018

Monkeypox — Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era

International Journal of Infectious Diseases
January 2019 Volume 78, p1-154   Open Access
https://www.ijidonline.com/issue/S1201-9712(18)X0012-5

Editorials

Monkeypox — Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era
Eskild Petersen, Ibrahim Abubakar, Chikwe Ihekweazu, David Heymann, Francine Ntoumi, Lucille Blumberg, Danny Asogun, Victor Mukonka, Swaib Abubaker Lule, Matthew Bates, Isobella Honeyborne, Sayoki Mfinanga, Peter Mwaba, Osman Dar, Francesco Vairo, Maowia Mukhtar, Richard Kock, Timothy D. McHugh, Giuseppe Ippolito, Alimuddin Zumla
p78–84
Published online: November 16, 2018

Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges

International Journal of Infectious Diseases
January 2019 Volume 78, p1-154   Open Access
https://www.ijidonline.com/issue/S1201-9712(18)X0012-5

Original Reports
Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges
Yibeltal Assefa, Charles F. Gilks, Judith Dean, Betru Tekle, Meskele Lera, Taye Tolera Balcha, Yimam Getaneh, Wim Van Damme, Peter S. Hill
p57–64
Published online: October 31, 2018